July 26, 2016 2:07 PM ET

Biotechnology

Company Overview of Profectus BioSciences, Inc.

Company Overview

Profectus BioSciences, Inc. develops preventive and therapeutic vaccines for infectious diseases and oncolytic vaccines for cancer immunotherapy. It develops prophylactic vaccines for public health and biodefense; therapeutic HIV vaccines; therapeutic HPV vaccine for use as an adjunct to surgery that targets the seven HPV types responsible for cervical cancer, and head and neck cancers; therapeutic vaccine that targets all eight HBV genotypes for use as an adjunct to drug therapy; and therapeutic vaccine for herpes simplex virus type-2. The company also develops vaccines for pre- and post-exposure protection against the hemorrhagic disease caused by Ebola and Marburg viruses; prophylactic va...

6411 Beckley Street

Suite 202

Baltimore, MD 21224

United States

Founded in 2002

Phone:

443-743-1100

Fax:

410-633-5709

Key Executives for Profectus BioSciences, Inc.

President and Director
Executive Chairman
Executive Director of Operations and Outsourcing
Chief Scientific Officer of Vaccines
Corporate Counsel
Compensation as of Fiscal Year 2016.

Profectus BioSciences, Inc. Key Developments

Profectus and Vyriad Form Global Collaboration to Develop Oncolytic Recombinant VSV (rVSV) Vaccines for Cancer Immunotherapy

Profectus BioSciences, Inc. and Vyriad announced an exclusive global collaboration to develop oncolytic vesiculovirus vaccines for the treatment of advanced-stage cancers. The two companies will combine and leverage their respective recombinant vesicular stomatitis virus (rVSV)-derived oncolytic and vaccine platform technologies to develop novel cancer drugs that selectively destroy tumor cells while simultaneously boosting patients' immune systems to continue killing any residual cancer cells that may survive the initial virus attack. The intellectual property licensed to Profectus and Vyriad that underlies the collaboration consolidates the platform technology first developed by John K. Rose, PhD, Professor of Pathology and Director of the Molecular Virology Program at Yale University. Dr. Rose's foundational technology established the use of recombinant vesiculoviruses in vaccine development, including the use of rVSV for the delivery of vaccine antigens as well as their use as oncolytic viruses. In nature, VSVs can be isolated from insects and livestock and are not considered human pathogens. However, VSVs can be engineered to selectively replicate in tumor cells and destroy them without harming healthy cells. Oncolytic vesiculoviruses have demonstrated potent ability to target and destroy cancer cells while also stimulating the body's adaptive anti-tumor immune response that directs the immune system to continue killing cancer cells. This anti-tumor immune response is more powerfully stimulated when the virus has been further engineered to encode a tumor antigen. Under the terms of the exclusive agreement, the collaboration will be strategically managed by a joint development committee with equal representation from Profectus and Vyriad, and Vyriad assumes the primary responsibility for program implementation. The companies' strategy is to show efficacy of the combination approach for an initial selected tumor indication, then proceed to develop a portfolio of oncolytic vaccines targeting different cancer indications, potentially in combination with other cancer immunotherapies such as checkpoint inhibitors, or other forms of therapy such as chemotherapy and newer targeted therapies. The companies anticipate the first program initiating human clinical trials in 2017. Financial terms of the agreement were not disclosed.

Profectus BioSciences Initiates Ebola Vaccine Phase 1 Clinical Trial

Profectus BioSciences, Inc. announced the initiation of a Phase 1 clinical study of Profectus' VesiculoVax™-vectored Ebola virus vaccine. The vaccine is a version of the company's patented VSV vector that has been engineered for safe use in humans and to express the surface protein of Ebola virus. In preclinical studies, a single dose of this vaccine completely protected monkeys against the strain of Ebola virus responsible for the recent outbreak in West Africa. The Phase 1, placebo-controlled, dose-escalation study will enroll 39 subjects into three groups that will receive progressively higher doses of the vaccine by intramuscular injection. The trial is designed to establish the safety and immunogenicity of the vaccine at dose levels that span the dose shown to protect monkeys. The Profectus Ebola vaccine programs are supported by the U.S. Department of Defense Medical Countermeasures Systems–Joint Vaccine Acquisition Program (MCS-JVAP) both directly and through contracts with Battelle, the Biomedical Advanced Research and Development Authority (BARDA), and the National Institutes of Health (NIH).

Profectus BioSciences, Inc. Announces the Results of Study Demonstrating That Single Dose of Vaccine Administered Using the VesiculoVax Vector Platform

Profectus BioSciences, Inc. announced the results of a study demonstrating that a single dose of vaccine administered using the company's VesiculoVax vector platform protects non-human primates against challenge with the 'Makona' strain of Ebola virus (previously referred to as the Ebola Guinea strain) that is responsible for the current Ebola outbreak in West Africa. Results of the study are published in the April 9, 2015 issue of the journal, Nature, in an article entitled, 'Single-Dose Attenuated VesiculoVax Vaccines Protect Primates Against Ebola Makona Virus.' The study was authored by researchers at Profectus and the University of Texas Medical Branch (UTMB) at Galveston. In this trial, two candidate VesiculoVax-vectored Ebola vaccines of intermediate and high attenuation were tested, and both were shown to provide complete, single-dose protection of rhesus macaques against illness and death from the Makona strain of Ebola from Guinea, which is responsible for the current outbreak in West Africa. Eight vaccinated and two unvaccinated control macaques were infected with a Makona strain of Ebola virus 28days after receiving a single injection of one of the vaccines. None of the monkeys vaccinated with either vaccine showed any severe signs of illness following infection with the virus, whereas the two unvaccinated animals succumbed to the disease on days seven and eight. Profectus' highly attenuated rVSVN4CT1 VesiculoVax vector used in this study is also the foundation of the Profectus Ebola and Marburg monovalent and trivalent vaccines in development by Profectus with support from the National Institutes of Health (NIH), the U.S. Department of Health and Human Services (HHS) Biomedical Advanced Research and Development Authority (BARDA), and the Department of Defense (DoD) Joint Vaccine Acquisition Program (JVAP). The VesiculoVax platform provides the flexibility to construct vaccine delivery vectors with different levels of attenuation, a capability that enables the identification of vaccines that provide complete protection with level of safety.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
May 5, 2016
--
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Profectus BioSciences, Inc., please visit www.profectusbiosciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.